Federal law restricts pharmacies and doctors from routinely preparing copies of ready-made medicines, as of September 26, 2026. It also limits very large amounts of those copies.
For one named patient, the prescriber can document a change that makes a meaningful medical difference for that person. Under the federal pharmacy rule, that can keep the changed medicine from being treated as a copy.
A price difference is not a meaningful medical difference under that rule.
Businesses that make batches under outsourcing rules also face federal limits on copies of approved medicines.
As of September 26, 2026, semaglutide and tirzepatide injection products were absent from FDA’s shortage list.
One pharmacy having no stock does not, on its own, put a medicine on FDA’s national shortage list.
- Ask: “What medical need requires this change, and which federal rule allows you to make it?”
- Ask what is different and why that difference matters for you.
- Ask how the medicine also meets Alabama’s notice; a doctor’s note alone does not answer that.
- If someone cites a shortage, ask whether the exact medicine is on FDA’s current national shortage list.